Skip to main content

MoneyWorks4Me

Sun Pharmaceutical Industries informs about press release

16 Oct 2023 Evaluate

Sun Pharmaceutical Industries has informed that it enclosed its Press Release relating to ‘Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma’. 

The above information is a part of company’s filings submitted to BSE.


Peers
Company Name CMP
Sun Pharma. Inds. 1885.10
Dr. Reddys Labs. 1390.50
Cipla 1414.95
Lupin 2010.00
Zydus Lifesciences 1195.05
View more..